Nebilet Plus (Hydrochlorothiazide, Nebivolol)

Nebivolol, the active ingredient in Nebilet Plus, is a beta‑blocker presented as an oral tablet for oral use. It helps lower blood pressure in adults with hypertension. Hydrochlorothiazide, also present in Nebilet Plus, is a thiazide diuretic that promotes fluid loss and further supports blood‑pressure control.

GNH USA supplies Nebilet Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebilet Plus is indicated for the management of elevated arterial pressure within the antihypertensive drug class.

Hypertension: reduces systolic and diastolic blood pressure in adults with primary hypertension. Essential hypertension: provides combined beta‑blockade and diuretic action for sustained pressure control. Stage 2 hypertension: offers an intensified therapeutic option when monotherapy is insufficient.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Cold extremities - Nausea or abdominal discomfort - Increased urinary frequency

Serious or Rare Side Effects: - Severe hypotension or syncope - Electrolyte disturbances such as hypokalemia - Acute gout attacks - Renal function impairment - Allergic reactions including rash or angioedema - Pancreatitis or severe abdominal pain

Before initiating therapy, clinicians should evaluate cardiovascular status and renal function, and monitor electrolytes during treatment.

Monitor blood pressure regularly: adjust dose if target not achieved. Assess renal function: avoid in severe renal impairment. Check serum electrolytes: especially potassium and sodium. Use caution in diabetic patients: may mask hypoglycaemia symptoms. Avoid abrupt discontinuation: taper to prevent rebound hypertension. Store at room temperature: keep in the original pack, protect from moisture.

Nebilet Plus may interact with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Concomitant use with other β‑blockers: risk of excessive bradycardia. - Potent CYP2D6 inhibitors (e.g., paroxetine, quinidine): increase nebivolol levels. - Other thiazide or loop diuretics: heightened electrolyte loss. - Non‑selective β‑blockers: additive cardiovascular depression. - MAO inhibitors: potential for severe hypotension.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may enhance hypotensive effect. - NSAIDs: can reduce diuretic efficacy and affect renal function. - Lithium: increased risk of lithium toxicity. - Antidiabetic agents: may require dose adjustment. - Calcium channel blockers: possible additive heart‑rate reduction.